88 completed, 17 unknown, 10 recruiting, 8 terminated. 138 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 138 | Completed 88, Unknown 17, Recruiting 10, Terminated 8, Withdrawn 5, Active not recruiting 4, Not yet recruiting 4, Enrolling by invitation 2 |
Follow Tauopathies: new trials by email Literature Review of Tauopathies trials Research Report on Tauopathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease Donanemab - Alzheimer Disease | Phase 4 | Not yet recruiting | Eli Lilly and Company | 50 | 2026-11-01 | 2026-10-15 |
| Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation Donanemab, Placebo - Down Syndrome (DS), Down Syndrome (Trisomy 21) | Phase 4 | Not yet recruiting | Michael Rafii, MD, PhD | 60 | 2026-08-01 | 2026-05-15 |
| Evaluation System for Lecanemab Efficacy Using Gold Electrode ECL to Monitor Alzheimer's Biomarkers Lecanemab - Alzheimer Disease | Phase 4 | Recruiting | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 100 | 2026-07-10 | 2026-07-07 |
| Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis Acoramidis (AG10) oral tablet - Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis | Phase 4 | Recruiting | Eidos Therapeutics, a BridgeBio company | 150 | 2026-07-01 | 2026-07-29 |
| Effects of Ginkgo Biloba on Blood Biomarkers in Mild Cognitive Impairment Ginkgo Biloba Extract 240 mg, Placebo - Mild Cognitive Impairment, Alzheimer's Disease | Phase 4 | Not yet recruiting | Hanyang University | 120 | 2026-06-01 | 2026-06-26 |
| A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE) Zunveyl® - Alzheimer Disease | Phase 4 | Recruiting | Alpha Cognition, Inc | 150 | 2026-05-20 | 2026-10-19 |
| A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland Recombinant zoster vaccine, Placebo - Herpes Zoster | Phase 4 | Recruiting | GlaxoSmithKline | 33609 | 2026-03-31 | 2026-05-12 |
| Pilot Study of StudyU for N-of-1 Trials in HFrEF Patients (N-of-1 App) beta blockers, StudyU Application - HFrEF - Heart Failure With Reduced Ejection Fraction, Heart Failure | Phase 4 | Enrolling by invitation | Weill Medical College of Cornell University | 5 | 2026-02-10 | 2026-02-19 |
| Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics Approachs Lecanemab 10 mg/kg, Conventional anti-dementia treatment group - Alzheimer s Disease, Alzheimer Dementia (AD) | Phase 4 | Recruiting | First Affiliated Hospital of Wenzhou Medical University | 200 | 2026-01-01 | 2026-05-22 |
| Histidine Oral Supplementation as a Therapeutic Modality for Alzheimer's Disease l-Histidine, Control - Alzheimer Disease | Phase 4 | Withdrawn | Wake Forest University Health Sciences | 2025-04-01 | 2025-04-27 | |
| Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease Memantine, Memantine Oral Tablet - Alzheimer Disease | Phase 4 | Completed | Carnot Laboratories | 105 | 2024-10-04 | 2026-02-18 |
| Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL) cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine) - Alzheimer Disease, Cholinesterase Inhibitors | Phase 4 | Not yet recruiting | University Hospital, Bordeaux | 1205 | 2024-06-01 | 2023-10-06 |
| Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease Daridorexant 50 mg, Placebo, Polysomnography - Alzheimer Disease, Insomnia Disorder | Phase 4 | Recruiting | University Hospital, Montpellier | 62 | 2024-03-13 | 2026-06-25 |
| 12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease Administer Leqemi 10 mg/kg, every two weeks. - Alzheimer's Disease(AD) | Phase 4 | Active not recruiting | Ruijin Hospital | 80 | 2024-02-01 | 2025-06-24 |
| An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease GV-971, Placebo - Alzheimer's Disease | Phase 4 | Recruiting | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | 1312 | 2023-08-31 | 2023-11-09 |
| Improvement Effect of Lacosamide and Levetiracetam on Cognitive in Alzheimer's Disease Patients With Epilepsy Lacosamide 100 mg, Levetiracetam 250mg - Alzheimer Disease 3, Epilepsy | Phase 4 | Unknown | Xiangya Hospital of Central South University | 140 | 2023-07-05 | 2023-08-04 |
| Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia Spironolactone, Placebo - Mild Cognitive Impairment, Alzheimer Disease | Phase 4 | Completed | Emory University | 25 | 2022-09-06 | 2026-10-30 |
| Efficacy and Safety of Memantine and Sodium Oligomannate in Patients With Moderate to Severe Alzheimer's Disease Memantine Oral Tablet, GV-971 capsule - Treatment, Efficacy | Phase 4 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 150 | 2022-07-01 | 2022-07-07 |
| Aβ Dynamics in LLMD Escitalopram Oxalate, Placebo - Alzheimer Disease, Major Depressive Disorder | Phase 4 | Recruiting | NYU Langone Health | 60 | 2022-02-04 | 2026-05-06 |
| Efficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer's Disease Choline Alfoscerate 400mg, Placebo - Alzheimer Disease | Phase 4 | Unknown | Daewoong Bio Inc. | 630 | 2022-01-20 | 2024-03-21 |
Showing 20 of 138. Sign in to see all of them.
Alzheimer Disease (136) · Dementia (31) · Cognitive Dysfunction (13) · Psychomotor Agitation (7) · Lethargy (5) · Depression (4) · Lewy Body Disease (4) · Plaque, Amyloid (4) · Psychotic Disorders (4) · Cognition Disorders (3) · Dementia, Vascular (3) · Sleep Initiation and Maintenance Disorders (3) · Aggression (2) · Anosmia (2) · Behavior (2)
Central Nervous System Diseases (138) · Nervous System Diseases (138) · Neurodegenerative Diseases (138) · Brain Diseases (137) · Mental Disorders (137) · Neurocognitive Disorders (136) · Dementia (106) · Pathological Conditions, Signs and Symptoms (27) · Neurologic Manifestations (22) · Signs and Symptoms (22) · Neurobehavioral Manifestations (17) · Behavior (13) · Cognition Disorders (12) · Behavioral Symptoms (11)
Donepezil (25) · Memantine (23) · Rivastigmine (13) · Galantamine (9) · Escitalopram (6) · Methylphenidate (5) · Risperidone (5) · florbetapir (5) · GV-971 (3) · 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole (2) · Ginkgo biloba extract (2) · Glycerylphosphorylcholine (2) · Lithium Carbonate (2) · Olanzapine (2) · Quetiapine Fumarate (2)
Novartis (7) · Novartis Pharmaceuticals (7) · Avid Radiopharmaceuticals (4) · Eisai Inc. (4) · Eisai Korea Inc. (4) · NYU Langone Health (4) · New York State Psychiatric Institute (4) · Green Valley (Shanghai) Pharmaceuticals Co., Ltd. (3) · VA Office of Research and Development (3) · Duke University (2) · Emory University (2) · Forest Laboratories (2) · H. Lundbeck A/S (2) · Institute of Psychiatry, London (2) · Janssen Korea, Ltd., Korea (2)
United States (59) · South Korea (13) · China (11) · France (7) · Germany (5) · Canada (4) · Israel (3) · Japan (3) · Spain (3) · United Kingdom (3) · Australia (2) · India (2) · Italy (2) · Norway (2) · Taiwan (2)
Davangere Devanand, M.D. (3) · Jihee Mun (2) · Adrian Leibovici MD (1) · Ahmed A Baig, M.D. (1) · Alberto Mimenza Alvarado, Dr. (1) · Alistair Burns (1) · Andrea Snow, PhD MS BS (1) · Ane Erdal, PhD candidate (1) · Anna Sverdlik, MD (1) · Antoine Trammell, MD, MPH (1) · Ariel Gildengers, MD (1)
PMID 33189083, PMID 39498781, PMID 10511011, PMID 10588403, PMID 10913502, PMID 11072948, PMID 16494088, PMID 17183151, PMID 17914039, PMID 18198262, PMID 18251622, PMID 18591575, PMID 19210951, PMID 19389332, PMID 19874395, PMID 20220576, PMID 20429946, PMID 21062616, PMID 21274364, PMID 21476613, PMID 21561398, PMID 21645184, PMID 21845596, PMID 22269160, PMID 22813231, PMID 23075176, PMID 23218100, PMID 23429813, PMID 24144505, PMID 24290367, PMID 25523430, PMID 26796681, PMID 26876309, PMID 27780331, PMID 27855483, PMID 28945120, PMID 29107051, PMID 29487556, PMID 29635383, PMID 29725986, PMID 29854939, PMID 30761509, PMID 31985467, PMID 32333591, PMID 32925060, PMID 32966585, PMID 33308285, PMID 33649343, PMID 35104057, PMID 37271721
2004 (1), 2009 (1), 2015 (1), 2017 (1), 2025 (1), I01RX003143 (1), R01AG011378 (1), R01AG018487 (1), R01AG021488 (1), R01AG041795 (1), R01AG051588 (1), R01AG055389 (1), R01AG059417 (1), R01AG093767 (1), R01MH043832 (1)